Report Corruption
Newsroom /

Hold Your Horses: The NIH’s Mysterious ‘Non-Recommendation’ for Ivermectin.

The NIH Says the Drug is Dangerous, But Conflicts of Interest May Cloud the Decision.


Photo for: Hold Your Horses: The NIH’s Mysterious ‘Non-Recommendation’ for Ivermectin.

Key Points

  • Ivermectin received a ‘non-recommendation’ from the NIH for treatment of COVID-19.
  • But research shows it may actually be useful, in some capacity, against COVID-19.
  • It’s already used to help fight 21 virus all over the world.
  • The reason for the NIH’s decision is shrouded in secrecy.

The discussion around the antiparasitic drug Ivermectin is cloudy: it’s a miracle cure; it’s a horse-dewormer; it’s incredibly dangerous; it’s safe and already widely-used. What’s the truth?

The National Institute of Health (NIH) has issued a firm “non-recommendation” when it comes to the usefulness of Ivermectin in the possible treatment of COVID-19. But before diving into the questionable circumstances surrounding that decision, let’s talk about Ivermectin.

According to The Wall Street Journal, Ivermectin is derived from a Nobel Prize-winning medicine called avermectin. Now, Ivermectin is widely used to fight more than 21 viruses world-wide, including SARS-CoV-2, the cause for COVID-19.

“A single dose [of ivermectin] reduced the viral load of SARS-CoV-2 in cells by 99.8% in 24 hours and 99.98% in 48 hours, according to a study published in the journal Antiviral Research,” WSJ reports.

There are also 70 clinical trials currently evaluating the usefulness of Ivermectin for treating Covid-19. Evidence suggests it may help in both treating and preventing the disease.

But the NIH still won’t recommend the drug for treatment, stating there is “insufficient evidence … to recommend either for or against the use of ivermectin for the treatment of COVID-19.”

The efficacy of Ivermectin for certain applications is clear. How the NIH reached their “non-recommendation” is not.

According to Peter Yim, who held a fellowship in the Clinical Center at the National Institutes of Health, “[the] NIH has gone to extreme efforts to avoid stating whether a vote was held to endorse the ivermectin non-recommendation. This includes fighting a Freedom of Information Act request in federal court.”

The group who issued the “non-recommendation” was “shrouded in mystery,” says Yim – until a recent FOIA request sent to the Center for Disease Control and Prevention. As it turns out, one of the group members has an extraordinary conflict of interest.

“[Group member] Susanna Naggie…received a $155 million grant for the study of Ivermectin following the non-recommendation. Funding for the study would have been difficult to justify if the drug was recommended for use in COVID-19,” Yim says.

With such a lack of transparency from the NIH, is it possible to get a straight answer on Ivermectin at all? Who will clear the smoke if our top, most-trusted institutions won’t come clean?

One thing is for certain: it’s not just a horse dewormer.